BioSpace News Archive

Spectral Medical Inc., announced that its wholly owned subsidiary, Dialco Medical Inc., has formed a Medical Advisory Board to support in guiding the DIMI usability trial and continued development of the DIMI device.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN.)

SOTIO Biotech announced today that it will deliver an oral presentation featuring interim safety and efficacy data from its Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, in combination with pembrolizumab, as well as two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.

PolarityTE, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock.

Tend (“the company”), a microbiome solutions company, today announced the initiation of clinical studies for its Gut Microbiome Collect and Prep (CAP) device to prepare capsules for Fecal Microbiota Transplant (FMT) for patients with recurrent Clostridium difficile (C. diff) infections.

InspireMD, Inc., a global developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced that it will host a Key Opinion Leader webinar on its CGuard Stent Platform and it’s MicroNet™ portfolio on Tuesday, March 22, 2022 at 2 p.m. Eastern Time.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced the appointment of Dr. Mel Spigelman, M.D., to its Board of Directors.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will report its financial results for the fourth quarter and full year 2021 on Monday, March 28, 2022.

NANOBIOTIX announces that it will report its financial results for full-year ending December 31, 2021, on Wednesday, March 30, 2022, after the close of the US market.